Cytomed Therapeutics Limited Stock Market Value
| GDTC Stock | 1.02 0.07 7.37% |
| Symbol | CytoMed |
Will Biotechnology sector continue expanding? Could CytoMed diversify its offerings? Factors like these will boost the valuation of CytoMed Therapeutics. Market participants price CytoMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CytoMed Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, CytoMed Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
CytoMed Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CytoMed Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CytoMed Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in CytoMed Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding CytoMed Therapeutics Limited or generate 0.0% return on investment in CytoMed Therapeutics over 90 days. CytoMed Therapeutics is related to or competes with Enlivex Therapeutics, MetaVia, NuCana PLC, Neurosense Therapeutics, Lisata Therapeutics, Collplant Biotechnologies, and Neuraxis. CytoMed Therapeutics is entity of United States More
CytoMed Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CytoMed Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CytoMed Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 35.71 | |||
| Value At Risk | (10.38) | |||
| Potential Upside | 8.33 |
CytoMed Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytoMed Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CytoMed Therapeutics' standard deviation. In reality, there are many statistical measures that can use CytoMed Therapeutics historical prices to predict the future CytoMed Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.79) | |||
| Total Risk Alpha | (1.28) | |||
| Treynor Ratio | (7.14) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CytoMed Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CytoMed Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (7.13) | |||
| Mean Deviation | 4.21 | |||
| Coefficient Of Variation | (845.74) | |||
| Standard Deviation | 6.58 | |||
| Variance | 43.3 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.79) | |||
| Total Risk Alpha | (1.28) | |||
| Treynor Ratio | (7.14) | |||
| Maximum Drawdown | 35.71 | |||
| Value At Risk | (10.38) | |||
| Potential Upside | 8.33 | |||
| Skewness | 0.4334 | |||
| Kurtosis | 5.71 |
CytoMed Therapeutics Backtested Returns
CytoMed Therapeutics secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. CytoMed Therapeutics Limited exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CytoMed Therapeutics' Mean Deviation of 4.21, risk adjusted performance of (0.09), and Standard Deviation of 6.58 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.11, which signifies not very significant fluctuations relative to the market. As returns on the market increase, CytoMed Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding CytoMed Therapeutics is expected to be smaller as well. At this point, CytoMed Therapeutics has a negative expected return of -0.84%. Please make sure to confirm CytoMed Therapeutics' day median price, price action indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if CytoMed Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.56 |
Modest predictability
CytoMed Therapeutics Limited has modest predictability. Overlapping area represents the amount of predictability between CytoMed Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CytoMed Therapeutics price movement. The serial correlation of 0.56 indicates that roughly 56.0% of current CytoMed Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.56 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:Check out CytoMed Therapeutics Correlation, CytoMed Therapeutics Volatility and CytoMed Therapeutics Performance module to complement your research on CytoMed Therapeutics. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
CytoMed Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.